This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Reverset, RVT, D-D4FC, DPC-817
Description: Reverset, a nucleoside analog that targets the HIV-1 reverse transcriptase enzyme, is being developed under an approved US FDA Investigational New Drug (IND) application for the treatment of HIV-infected individuals. Preclinical in vitro studies have shown that Reverset inhibits replication of drug-resistant HIV strains commonly seen after treatment with zidovudine (ZDV) and lamivudine (3TC).
Deal Structure: Pharmasset and Incyte announced a collaborative license agreement in September 2003 to develop and commercialize Reverset. Pharmasset will receive from Incyte future performance milestone payments and royalties on net sales in exchange for exclusive rights in the U.S., Europe and certain other markets to develop, manufacture and market the drug. Pharmasset retained development, marketing and commercialization rights in certain territories, including Mexico, Central and South America, Africa, the Middle East, Korea and China.
In November 2011, Gilead and Pharmasset announced that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash. The transaction values Pharmasset at approximately $11 billion. In January 2012, Gilead announced the successful completion of the tender offer for all of the outstanding shares of common stock of Pharmasset.
Partners: Gilead Sciences, Inc.
Pink Sheet Incyte drops HIV drug
Additional information available to subscribers only: